Jenoptik’s business development in H1 2025 affected by challenging market environment
Improved demand in the second quarter Revenue, earnings, and order intake, however, were below the prior year's level Fi…
Improved demand in the second quarter Revenue, earnings, and order intake, however, were below the prior year's level Fi…
Option framework agreement with SERI establishes ownership- and revenue-sharing model for all NOX-E36 ophthalmic disease…
Das innovative Biotech-Unternehmen NurExone, das sich auf exosom-basierte Therapien zur Behandlung von Verletzungen des…
VeonGen advances two proprietary, first-in-class gene therapies in the clinic, enabled by its novel vgRNA REVeRT and vgA…
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) („NurExone“ oder das „Unternehmen“), ein biotechnologisches…
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) („NurExone“ oder das „Unternehmen“), ein biotechnologisches…
Diede van den Ouden, an experienced CEO with successful background in small-cap turnarounds, to be nominated for appoint…
Total €7.6 million raised through multiple transactions All convertible debt instruments removed from balance sheet dur…
Zwischen spannenden Vorträgen, neuen Impulsen aus Forschung, Therapie-, Pflegepraxis und lebhaftem Austausch unter Kolle…
. TME Pharma and Singapore Eye Research Institute (SERI) file new patent applications covering NOX-E36 for treatment o…